The recent Ebola outbreak in Africa coincides with a massive Meningitis Vaccine campaign targeting over 100 million Africans; notably including all four African countries (Guinea, Nigeria, Liberia, Sierra Leone) caught in the epicentre of the viral spread. The cost-effective vaccine, MenAfriVac®,(less than US$0.50 per dose) was “kept outside the cold chain for up to four days at up to 40°C”. ... Symptoms of ‘Acute fulminating Meningococcal Septicemia’, a virulent form of bacterial meningitis (marked by extreme vomiting, hemorrhaging – excessive bleeding around the eyes & mouth, severe blackish bruising on the arms & legs), closely resemble those seen in Ebola victims. Heinz Feldmann, MD and Thomas W Geisbert, PhD, The Lancet
Posted on: Mon, 06 Oct 2014 08:34:29 +0000
Trending Topics
Recently Viewed Topics
© 2015